Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 5/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 3/20 | 0.39 |
| ▸ | MC3R | P41968 | 3/20 | 0.39 |
| ▸ | MC1R | Q01726 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7076292 | 0.90 | CTSC (0.48) | CA12CA1CA2CA4CA5A | |
| SCHEMBL5364821 | 0.86 | CTSL (0.46) | CTSCCTSLOPRL1CTSBCTSS | |
| SCHEMBL5372395 | 0.85 | CTSC (0.47) | CTSCCTSLDPP4CTSBCTSS | |
| SCHEMBL5357617 | 0.84 | CTSS (0.48) | CA12CA1CA2CA4CA5A | |
| SCHEMBL6107836 | 0.81 | CTSS (0.51) | CTSLCTSBCTSSCTSK | |
| SCHEMBL7083037 | 0.80 | CTSL (0.43) | CTSLCTSBCTSSCTSK | |
| SCHEMBL7075165 | 0.76 | CTSC (0.49) | CTSCCTSLDPP4CTSBCTSS | |
| SCHEMBL7075206 | 0.75 | CTSL (0.50) | CTSCCTSLCTSBCTSSCTSK | |
| SCHEMBL5364103 | 0.75 | CTSL (0.45) | CTSCCTSLCTSBCTSSCTSK | |
| SCHEMBL7076015 | 0.75 | CTSL (0.49) | CTSCCTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | claimed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | claimed |
| US-7279472-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7265132-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7056915-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6756372-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, CROHN'S DISEASE, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, PSORIASIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CA12 1055/4885CA1 286/4885CA2 350/4885 |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CA12 1154/4885CA1 277/4885CA2 361/4885 |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CA12 1093/4885CA1 258/4885CA2 341/4885 |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CA12 1154/4885CA1 277/4885CA2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.